m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05208
 [1]
Non-coding RNA LINC00659 ALKBH5  lncRNA       miRNA   circRNA Direct Enhancement m6A modification JAK1 JAK1 ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Tyrosine-protein kinase JAK1 (JAK1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long intergenic non-protein coding RNA 659 (LINC00659) LncRNA View Details
Regulated Target RNA demethylase ALKBH5 (ALKBH5) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising Tyrosine-protein kinase JAK1 (JAK1) mRNA in an m6 A-YTHDF2-dependent manner
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
In-vitro Model
 BGC-823 Gastric carcinoma Homo sapiens CVCL_3360
In-vivo Model BGC-823 (3 × 106) cells that stably expressed or silenced ALKBH5 and LINC00659 and their paired control cells were injected into the left side of each mouse. For cell metastasis experiments in vivo, BGC-823 (3 × 106) cells that stably overexpressed or silenced ALKBH5 and LINC00659 and their paired control cells were injected through tail vein.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Tyrosine-protein kinase JAK1 (JAK1) 88 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Upadacitinib Approved [2]
Synonyms
ABT-494
    Click to Show/Hide
MOA Modulator
Activity IC50 = 8 nM
External Link
CID: 58557659
TTD: D07JAG
DrugBank: DB15091
 Compound Name Momelotinib Approved [3]
Synonyms
Cyt387; 1056634-68-4; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
    Click to Show/Hide
MOA Modulator
Activity IC50 = 11 nM
External Link
CID: 25062766
TTD: D0D5ZJ
DrugBank: DB11763
 Compound Name Ruxolitinib Approved [4]
Synonyms
Ruxolitinib (JAK inhibitor)
    Click to Show/Hide
MOA Modulator
Activity Ki = 0.09 nM
External Link
CID: 25126798
TTD: D04LKS
DrugBank: DB08877
 Compound Name Abrocitinib Approved [5]
MOA Inhibitor
Activity IC50 = 29 nM
External Link
CID: 78323835
TTD: D05PCM
DrugBank: DB14973
 Compound Name Baricitinib Approved [6]
Synonyms
Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
    Click to Show/Hide
MOA Modulator
Activity IC50 = 0.99 nM
External Link
CID: 44205240
TTD: D0Y7IC
DrugBank: DB11817
 Compound Name SHR0302 Phase 3 [7]
Synonyms
(3AR,5S,6AS)-N-(3-METHOXY-1,2,4-THIADIAZOL-5-YL)-5-(METHYL (7H-PYRROLO(2,3- D)PYRIMIDIN-4-YL)AMINO) HEXAHYDROCYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE; (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl (7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino) hexahydrocyclopenta(c)pyrrole-2(1H)-carboxamide; (3aR,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide; 1445987-21-2; AC-36766; AKOS040759719; CHEMBL5095398; CS-0062969; CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, HEXAHYDRO-N-(3-METHOXY-1,2,4- THIADIAZOL-5-YL)-5-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-; Cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3aalpha,5alpha,6aalpha)-; EX-A5101; example 34 [WO2013091539A1]; F82248; GTPL11878; HY-112724; Ivarmacitinib; IVARMACITINIB [INN]; Ivarmacitinib [USAN]; K6K4B9Z5TV; MS-27180; NCGC00687790-01; rel-(3aR,5s,6aS)-N-(3-Methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide; SCHEMBL15077696; SCHEMBL15077710; SCHEMBL16191633; SHR0302; SHR-0302; SHR0302 base; SHR0302 FREE BASE; SHR-0302 FREE BASE; UNII-K6K4B9Z5TV; US9527851, 34; US9527851, 74; WHO 11823
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 71622431
TTD: DFK8Z5
 Compound Name ASP-015K Phase 3 [8]
Synonyms
Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; D10653; Peficitinib pound A
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.9 nM
External Link
CID: 57928403
TTD: D06EIC
DrugBank: DB11708
 Compound Name GSK2586184 Phase 2 [9]
Synonyms
GSK-2586184
    Click to Show/Hide
MOA Modulator
External Link
CID: 44603362
TTD: D06HZA
 Compound Name INCB54707 Phase 2 [10]
MOA Inhibitor
External Link
TTD: D0HJ1R
 Compound Name GLPG-0634 Phase 2 [6]
Synonyms
Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
    Click to Show/Hide
MOA Modulator
Activity IC50 = 10 nM
External Link
CID: 49831257
TTD: D0SG7B
DrugBank: DB14845
 Compound Name EQ121 Phase 2 [11]
MOA Inhibitor
External Link
TTD: DD6A7P
 Compound Name CTP-543 Phase 2 [12]
MOA Inhibitor
External Link
TTD: D01UAU
 Compound Name INCB039110 Phase 2 [8]
Synonyms
Examlpe 294 [WO2011112662]
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 53380437
TTD: D09AFI
DrugBank: DB12154
 Compound Name PF-06700841 Phase 2 [10]
Synonyms
BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118878093
TTD: D0V4DX
DrugBank: DB15003
 Compound Name ATI-501 Phase 2 [13]
MOA Inhibitor
External Link
TTD: D6INZ9
 Compound Name ATI-502 Phase 2 [14]
Synonyms
ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46851625
TTD: D6N5UC
 Compound Name A223 Phase 2 [15]
MOA Inhibitor
External Link
TTD: DH0A6O
 Compound Name CTP-543 Phase 2 [16]
Synonyms
Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72704611
TTD: DU10JI
 Compound Name TD-8236 Phase 2 [17]
MOA Inhibitor
External Link
TTD: D2KTG5
 Compound Name Cerdulatinib Phase 2 [10]
Synonyms
PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 12 nM
External Link
CID: 44595079
TTD: D0BI3N
DrugBank: DB15499
 Compound Name ALXN2075 Phase 1/2 [18]
MOA Inhibitor
External Link
TTD: D2JZ3U
 Compound Name AZD0449 Phase 1 [19]
MOA Inhibitor
External Link
TTD: D63WFO
 Compound Name KN-002 Phase 1 [20]
MOA Inhibitor
External Link
TTD: DI19BZ
 Compound Name AZD4604 Phase 1 [21]
Synonyms
(2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-; 2241039-81-4; AKOS040733485; AT39356; AZD4604; AZD-4604; BDBM488779; CHEMBL4447181; CS-0101485; EX-A5343; example 35 [WO2018134213A1]; GTPL11716; HY-126294; JAC34RRR7S; JAK1-IN-7; londamocitinib; MS-30607; SCHEMBL20399395; UNII-JAC34RRR7S; US10961228, Example 35
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135240395
TTD: DX72LV
 Compound Name PF-07295324 Phase 1 [22]
MOA Inhibitor
External Link
TTD: DXVA93
 Compound Name GDC-0214 Phase 1 [23]
Synonyms
1831144-46-7; AKOS040759985; BDBM232517; CHEMBL3964801; EX-A6434; GDC0214; GDC-0214; GTPL12318; iJak-381; N-(3-(5-Chloro-2-(difluoromethoxy)phenyl)-1-(2-(4-((2-cyanoethyl)(methyl)amino)piperidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[3-[5-chloro-2-(difluoromethoxy)phenyl]-1-[2-[4-[2-cyanoethyl(methyl)amino]piperidin-1-yl]-2-oxoethyl]pyrazol-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [3-(5-chloro-2-difluoromethoxy-phenyl)-1-(2-{4-[(2-cyano-ethyl)-methyl-amino]-piperidin-1-yl}-2-oxo-ethyl)-1H-pyrazol-4-yl]-amide; RG6151; RG-6151; SCHEMBL17271636; US9346815, 63
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118522534
TTD: DZ2RH6
 Compound Name Cyclohexyl azetidine derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure13Example1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 10 nM
External Link
TTD: D00GJY
 Compound Name Bipyrazole derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure13Example17
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 300 nM
External Link
TTD: D0H3KF
 Compound Name Tricyclic compound 3 Patented [24]
Synonyms
PMID27774824-Compound-Figure13Example20
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D0OS1N
 Compound Name Triazolo-pyridine derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure7ExampleI-286
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.27 nM
External Link
TTD: D00JUI
 Compound Name Imidazopyridazine derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure5Example75
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6.7 nM
External Link
TTD: D00PTE
 Compound Name Pyrrolo-pyridone derivative 2 Patented [25]
Synonyms
PMID27774822-Compound-Figure2ExampleII-92
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.07 nM
External Link
TTD: D03PBI
 Compound Name PMID27774822-Compound-Figure7Example63 Patented [25]
MOA Inhibitor
Activity Ki = 0.34 nM
External Link
TTD: D04OCD
 Compound Name Cyclic cyanoethypypazole derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example14-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 nM
External Link
TTD: D05GEL
 Compound Name Pyrrolo-pyridone derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example1-19
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.05 nM
External Link
TTD: D06MQB
 Compound Name Imidazopyridazine derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure5Example1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
TTD: D07BND
 Compound Name PMID27774824-Compound-Figure6Example6 Patented [24]
MOA Inhibitor
Activity IC50 = 39 nM
External Link
TTD: D0F3BK
 Compound Name Geminally-substituted cyanoethylpypazolo pyridone derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example17-32
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.04 nM
External Link
TTD: D0H6XN
 Compound Name Cyanomethyl pypazole carboxamide derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example40-85
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.02 nM
External Link
TTD: D0K2RW
 Compound Name Geminally-substituted cyanoethylpypazolo pyridone derivative 2 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example5-84
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 0.02 nM
External Link
TTD: D0KI5F
 Compound Name Cycloalkyl nitrile pyrazolo pyridone derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example15-71
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.069 nM
External Link
TTD: D0PB5X
 Compound Name PMID27774824-Compound-Figure7Example10 Patented [24]
MOA Inhibitor
Activity IC50 = 83 nM
External Link
TTD: D0PM8K
 Compound Name Cycloalkyl nitrile pyrazolo pyridone derivative 2 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example3-9
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.081 nM
External Link
TTD: D0S4TH
 Compound Name Pyrrolo-pyridone derivative 3 Patented [25]
Synonyms
PMID27774822-Compound-Figure9Example4
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0T6CY
 Compound Name Cycloalkyl nitrile pyrazole carboxamide derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure2Example1-4
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.5 nM
External Link
TTD: D0V0KI
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 11 Patented [24]
Synonyms
PMID27774824-Compound-Figure13Example25
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 20 nM
External Link
TTD: D0VQ7P
 Compound Name Ruxolitinib derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure4Example4
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 to 100 nM
External Link
TTD: D01EYJ
 Compound Name Five-and-six-membered heterocyclic compound 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure8compoundT-38
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D08WPB
 Compound Name Pyrazolopyridine derivative 4 Patented [25]
Synonyms
PMID27774822-Compound-Figure9Example1
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09RUN
 Compound Name Pyrrole six-membered heteroaryl ring derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure1Example6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
TTD: D09UBE
 Compound Name PMID27774824-Compound-Figure2Example4 Patented [24]
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D0A6RG
 Compound Name Tricyclic compound 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure1Example1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.3 nM
External Link
TTD: D0G0FK
 Compound Name Isoxazole derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure11compound1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 190 nM
External Link
TTD: D0G9MM
 Compound Name PMID27774822-Compound-Figure1Example20 Patented [25]
MOA Inhibitor
Activity IC50 = 0.5 nM
External Link
TTD: D0M3CB
 Compound Name Isoxazole derivative 2 Patented [25]
Synonyms
PMID27774822-Compound-Figure11compound2
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
TTD: D0TX2G
 Compound Name Pyrrolo-pyridine derivative 3 Patented [25]
Synonyms
PMID27774822-Compound-Figure8Example55
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000 nM
External Link
TTD: D0VR6E
 Compound Name N-methylmethanesulfonamide derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure4Example22
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
TTD: D0XH7H
 Compound Name N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure5Example25
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 12 nM
External Link
TTD: D0Y2IM
 Compound Name Pyrrole derivative 7 Patented [25]
Synonyms
PMID27774822-Compound-Figure3compound229
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
TTD: D0YJ4D
 Compound Name Benzimidazole derivative 7 Patented [24]
Synonyms
PMID27774824-Compound-Figure11Example15
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.1 to 50 nM
External Link
TTD: D01CRX
 Compound Name Bis-aminopyrimidine derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure7compound23
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
TTD: D01FVC
 Compound Name Pyrazolopyridine derivative 3 Patented [25]
Synonyms
PMID27774822-Compound-Figure5Example131
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 0.5 nM
External Link
TTD: D03QAY
 Compound Name Tricyclic pyrrolopyridine compound 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure3Example45
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.1 nM
External Link
TTD: D04BOW
 Compound Name Aminooxazole carboxamide derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure6Example25
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 29 nM
External Link
TTD: D05AXE
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 6 Patented [25]
Synonyms
PMID27774822-Compound-Figure5Example10
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
TTD: D0FQ4Z
 Compound Name PMID27774824-Compound-Figure6Example12 Patented [24]
MOA Inhibitor
Activity IC50 = 1 nM
External Link
TTD: D0GB7G
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 8 Patented [25]
Synonyms
PMID27774822-Compound-Figure5Example2
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 29 nM
External Link
TTD: D0KL3B
 Compound Name Bis-aminopyrimidine derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure7Example103
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D0LR6J
 Compound Name Tricyclic compound 11 Patented [25]
Synonyms
PMID27774822-Compound-Figure7Example34
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.5 nM
External Link
TTD: D0LS1O
 Compound Name Tricyclic heterocycle derivative 5 Patented [25]
Synonyms
PMID27774822-Compound-Figure7Example4
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.03 nM
External Link
TTD: D0M2WA
 Compound Name PMID27774822-Compound-Figure11Example5 Patented [25]
MOA Inhibitor
Activity IC50 = 10 nM
External Link
TTD: D0RJ3W
 Compound Name Bis-aminopyrimidine derivative 3 Patented [24]
Synonyms
PMID27774824-Compound-Figure7Example25
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
TTD: D0S6XT
 Compound Name Bis-aminopyrimidine derivative 4 Patented [24]
Synonyms
PMID27774824-Compound-Figure7Example83
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1000 to 10000 nM
External Link
TTD: D0SJ1Q
 Compound Name PMID27774824-Compound-Figure3Example18 Patented [24]
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
TTD: D0U1HA
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 7 Patented [25]
Synonyms
PMID27774822-Compound-Figure5Example14
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 42 nM
External Link
TTD: D0U5FZ
 Compound Name Pyrimidopyridazinone derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure10Example7
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.7 nM
External Link
TTD: D0WA1V
 Compound Name Tricyclic heterocycle derivative 1 Patented [25]
Synonyms
PMID27774822-Compound-Figure3Example81
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.8 nM
External Link
TTD: D0X1FD
 Compound Name Imidazo[4,5-c]pyridine derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure11Example228
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.01 to 100 nM
External Link
TTD: D07PTU
 Compound Name PMID27774824-Compound-Figure9Example2up Patented [24]
MOA Inhibitor
Activity IC50 = 3400 nM
External Link
TTD: D0WZ8N
 Compound Name PMID27774824-Compound-Figure9Example2down Patented [24]
MOA Inhibitor
Activity IC50 = 3000 nM
External Link
TTD: D01DBB
 Compound Name Aminotriazolopyridine derivative 1 Patented [24]
Synonyms
PMID27774824-Compound-Figure11Example1down
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 550 nM
External Link
TTD: D09ALF
 Compound Name Imidazo[4,5-c]pyridine derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure11Example82
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.01 to 100 nM
External Link
TTD: D0VJ1R
 Compound Name PMID27774824-Compound-Figure11Example1up Patented [24]
MOA Inhibitor
Activity IC50 = 2.6 nM
External Link
TTD: D0YR8S
 Compound Name Pyrazolo[4,3-c]pyridine derivative 2 Patented [24]
Synonyms
PMID27774824-Compound-Figure7compound1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
TTD: D09PIS
 Compound Name INCB47986 Discontinued in Phase 2 [6]
MOA Inhibitor
External Link
TTD: D0HB4E
 Compound Name ZM-39923 Investigative [26]
Synonyms
ZM39923; 273727-89-2; UNII-M0ZX82000S; M0ZX82000S; 3-[benzyl(propan-2-yl)amino]-1-(naphthalen-2-yl)propan-1-one; 3-(Benzyl(propan-2-yl)amino)-1-(naphthalen-2-yl)propan-1-one; JSASWRWALCMOQP-UHFFFAOYSA-N; Tocris-1367; NCGC00025126-01; AC1L1GQH; Lopac-Z-4626; Lopac0_000844; SCHEMBL2891331; GTPL5994; CHEMBL596674; CHEBI:92715; BDBM81346; CTK6A9359; M9440 (Me-3,4-dephostatin); ZINC1487934; HY-12589A; HSCI1_000104; AKOS030526763; CS-4952; CCG-204927; NCGC00025126-02; NCGC00016107-05; NCGC00016107-02; NCGC00016107-09
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3797
TTD: D0YX5U
 Compound Name PMID24359159C19a Investigative [27]
Synonyms
UNII-7N5LJ2Z26C; 7N5LJ2Z26C; GTPL6977; BDBM50446982
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 3 nM
External Link
CID: 45275255
TTD: D0US9O
 Compound Name WHI-P154 Investigative [28]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
CID: 3795
TTD: D0E5IP
2B72: Gastric cancer 81 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Leniolisib Approved [29]
Synonyms
1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
    Click to Show/Hide
External Link
CID: 57495353
TTD: DGO2C1
 Compound Name Atezolizumab Approved [30]
External Link
TTD: D0YM2K
 Compound Name Bavencio Approved [30]
External Link
TTD: D0W8HN
 Compound Name Tebentafusp Approved [31]
External Link
TTD: D0S0BJ
 Compound Name Merimepodib Approved [32]
Synonyms
Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
    Click to Show/Hide
External Link
CID: 153241
TTD: D0F0ZE
DrugBank: DB04862
 Compound Name Taxol Approved [33]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ramucirumab Approved [34]
Synonyms
LY3009806
    Click to Show/Hide
External Link
TTD: D09HVD
 Compound Name Tucatinib Approved [35]
Synonyms
Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
    Click to Show/Hide
External Link
CID: 51039094
TTD: D09GRX
DrugBank: DB11652
 Compound Name Antacids Approved [36]
External Link
TTD: D06AJL
 Compound Name Trastuzumab Approved [30]
Synonyms
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
    Click to Show/Hide
External Link
TTD: D04WFL
 Compound Name Carbamazepine Phase 3 [37]
Synonyms
Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
    Click to Show/Hide
External Link
CID: 2554
TTD: D04MSM
DrugBank: DB00564
 Compound Name Margetuximab Approved [30]
External Link
TTD: D01YYP
 Compound Name Nivolumab Approved [30]
External Link
TTD: D00GOV
 Compound Name GRANITE Phase 3 [38]
Synonyms
Penoxsulam; 219714-96-2; 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; UNII-784ELC1SCZ; 784ELC1SCZ; CHEBI:81776; 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Penoxsulam [ISO]; PXD; DSSTox_CID_14803; DSSTox_RID_79204; DSSTox_GSID_34803; SCHEMBL116968; CHEMBL1895913; DTXSID0034803; HSDB 7887; AMY12535; BCP18718; EBD18529; Tox21_301010; MFCD07363876; ZINC13827750; AKOS025401685; NCGC00163715-01; NCGC00163715-02; NCGC00163715-03; NCGC00254912-01; AC-24494; Penoxsulam 100 microg/mL in Acetonitrile; CAS-219714-96-2; FT-0696708; Penoxsulam, PESTANAL(R), analytical standard; C18481; Q22808507; 2-(2,2-Difluoroethoxy)-6-trifluoromethyl-N-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide; 2-(2,2-Difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; 2-(2,2-difluoroethoxy)-N-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide; 2-(2,2-difluoroethyl)-N-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide; Benzenesulfonamide, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-
    Click to Show/Hide
External Link
CID: 11784975
TTD: DKF9I3
 Compound Name Zolbetuximab Phase 3 [39]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name Tusamitamab ravtansine Phase 3 [40]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name Andecaliximab Phase 3 [41]
External Link
TTD: D0Z6SP
 Compound Name ABP 980 Phase 3 [42]
External Link
TTD: D0WZ0X
 Compound Name GS-5745 Phase 3 [33]
External Link
CID: 56776542
TTD: D0WL0Q
 Compound Name S-1 Phase 3 [43]
Synonyms
Ciprofibrate-coa; Ciprofibrate-coenzyme A; Coenzyme A, ciprofibrate-; AC1L4TRG; AC1Q3T4H; 111900-25-5; s-{1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3; E5,5; E5-diphosphaheptadecan-17-yl} 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanethioate(non-preferred name); Coenzyme A, S-(2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoate)
    Click to Show/Hide
External Link
CID: 163872
TTD: D0S8LJ
 Compound Name Lonsurf Phase 3 [30]
External Link
TTD: D0PM0Y
 Compound Name GDC-0068 Phase 3 [33]
Synonyms
RG7440
    Click to Show/Hide
External Link
CID: 24788740
TTD: D0I4TH
DrugBank: DB11743
 Compound Name Edotecarin Phase 3 [44]
Synonyms
ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
    Click to Show/Hide
External Link
CID: 9808998
TTD: D0I1DW
DrugBank: DB04882
 Compound Name RG3638 Phase 3 [45]
Synonyms
Onartuzumab
    Click to Show/Hide
External Link
TTD: D0H9PT
 Compound Name G17DT Phase 3 [46]
Synonyms
Gastrimmune; Insegia
    Click to Show/Hide
External Link
TTD: D0G8ZQ
 Compound Name DE-766 Phase 3 [47]
External Link
TTD: D0FJ1W
 Compound Name Tesetaxel Phase 2 [48]
Synonyms
DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
    Click to Show/Hide
External Link
CID: 6918574
TTD: D0F9VH
DrugBank: DB12019
 Compound Name Nelipepimut S Phase 3 [49]
Synonyms
E75
    Click to Show/Hide
External Link
CID: 9941306
TTD: D0F8UV
 Compound Name BMS-986205 Phase 3 [30]
Synonyms
KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
    Click to Show/Hide
External Link
CID: 121328278
TTD: D0DP5I
DrugBank: DB14986
 Compound Name Rivoceranib Phase 3 [30]
External Link
TTD: D0D7BX
 Compound Name Claudiximab Phase 3 [30]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name OS-440 Phase 3 [50]
Synonyms
CNS modulator (spasticity), Osmotica
    Click to Show/Hide
External Link
TTD: D09OHH
 Compound Name Oraxol Phase 3 [30]
External Link
TTD: D04UWU
 Compound Name ICI 118,551 Phase 3 [33]
Synonyms
Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
    Click to Show/Hide
External Link
CID: 3682
TTD: D04DJS
 Compound Name Evorpacept Phase 2/3 [51]
Synonyms
ALX148
    Click to Show/Hide
External Link
TTD: DRP8H0
 Compound Name BNT141 Phase 2 [52]
External Link
TTD: DFZ19J
 Compound Name Anti-LAG3 Phase 2 [42]
External Link
TTD: D0T7OI
 Compound Name GSK1292263 Phase 2 [53]
External Link
CID: 24996872
TTD: D0S4II
DrugBank: DB12627
 Compound Name MM-111 Phase 2 [54]
External Link
TTD: D0Q2KM
 Compound Name Plevitrexed Phase 2 [55]
Synonyms
ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
    Click to Show/Hide
External Link
CID: 135430970
TTD: D0I9GR
DrugBank: DB06163
 Compound Name DS-8201 Phase 1 [42]
Synonyms
9-Aminofluorene; 9H-Fluoren-9-amine; 525-03-1; FLUOREN-9-AMINE; Fluoren-9-ylamine; UNII-4NHO2K4K5B; CCRIS 7000; BRN 2209545; 4NHO2K4K5B; OUGMRQJTULXVDC-UHFFFAOYSA-N; fluorene-9-ylamine; 9-Amino-fluoren; 9-amino-fluorene; 9H-9-fluorenamine; 9H-fluoren-9-yl-amine; AC1L1VP5; 4-12-00-03390 (Beilstein Handbook Reference); SCHEMBL353865; AC1Q53A2; AC1Q53A1; KS-00000JGC; CTK1H0380; DTXSID90200496; MolPort-001-794-448; HMS1780P20; 9H-fluoren-9-ylamine hydrochloride; ZINC1724407; ALBB-023296; CA-733; SBB005783; AKOS000264388; MCULE-8757055914; DS-
    Click to Show/Hide
External Link
CID: 10671
TTD: D0E8IQ
 Compound Name XL880 Phase 2 [56]
Synonyms
GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
    Click to Show/Hide
External Link
CID: 42642645
TTD: D0D1GF
DrugBank: DB12307
 Compound Name Matuzumab Phase 2 [57]
Synonyms
EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0BZ7V
 Compound Name BAY-57-9352 Phase 2 [33]
Synonyms
Telatinib; Bay 57-9352
    Click to Show/Hide
External Link
CID: 9808844
TTD: D07NOI
DrugBank: DB15393
 Compound Name Bemarituzumab Phase 2 [58]
External Link
TTD: D05ISO
 Compound Name PEGPH20 Phase 2 [30]
External Link
TTD: D05INV
 Compound Name Plevitrexed (R)-isomer Phase 2 [59]
Synonyms
YW3548
    Click to Show/Hide
External Link
CID: 213022
TTD: D04FYZ
 Compound Name APR-246 Phase 2 [60]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name CRS-207 Phase 2 [49]
External Link
TTD: D02WSB
 Compound Name Opdivo + Yervoy Phase 3 [30]
External Link
TTD: D02VYE
 Compound Name CT-041 Phase 1/2 [61]
External Link
TTD: DJ6AW5
 Compound Name BPX-601 Phase 1/2 [62]
External Link
TTD: D0TY6U
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [63]
External Link
TTD: D0C9MJ
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [64]
External Link
TTD: D0BE6M
 Compound Name Anti-HER2 CAR-T Phase 1/2 [65]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [66]
External Link
TTD: D08QYW
 Compound Name PAT-SC1 Phase 1/2 [67]
Synonyms
SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
    Click to Show/Hide
External Link
TTD: D00UOQ
 Compound Name ASP2138 Phase 1 [68]
External Link
TTD: DTQL30
 Compound Name SAR443216 Phase 1 [69]
External Link
TTD: DL6F3E
 Compound Name AMG 199 Phase 1 [70]
External Link
TTD: DEP3Z8
 Compound Name AMG 910 Phase 1 [71]
External Link
TTD: DEDP81
 Compound Name Alofanib Phase 1 [72]
Synonyms
1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
    Click to Show/Hide
External Link
CID: 86280646
TTD: D47MOS
 Compound Name HER2-specific CAR T cell Phase 1 [73]
External Link
TTD: D0YF6K
 Compound Name Anti-CEA-CAR T Phase 1 [74]
External Link
TTD: D0S1QN
 Compound Name XR-5944 Phase 1 [75]
Synonyms
MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
    Click to Show/Hide
External Link
CID: 439035
TTD: D0Q5TH
DrugBank: DB06364
 Compound Name A168 Phase 1 [15]
External Link
TTD: D0L9PU
 Compound Name EGFR806-specific CAR T cell Phase 1 [76]
External Link
TTD: D0I7ZH
 Compound Name AbGn-107 Phase 1 [30]
External Link
TTD: D08GZE
 Compound Name FPA144 Phase 1 [42]
External Link
TTD: D06NND
 Compound Name Minnelide 001 Phase 1 [33]
External Link
TTD: D05UFJ
 Compound Name CAR-T cells targeting EpCAM Phase 1 [77]
External Link
TTD: D01TNK
 Compound Name Anti-CEA CAR-T cells Phase 1 [78]
External Link
TTD: D00KDQ
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [79]
External Link
TTD: D0T8DD
 Compound Name PMID28460551-Compound-1 Patented [80]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 Patented [81]
Synonyms
PMID28621580-Compound-WO2012084683c62
    Click to Show/Hide
External Link
TTD: D04PKQ
 Compound Name TOPIXANTRONE HYDROCHLORIDE Discontinued in Phase 2 [82]
Synonyms
SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
    Click to Show/Hide
External Link
CID: 6918273
TTD: D06DWQ
 Compound Name MDL 101,731 Discontinued in Phase 2 [83]
Synonyms
Tezacitabine; Fmdc cpd; 130306-02-4; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
    Click to Show/Hide
External Link
CID: 6435808
TTD: D05HZI
DrugBank: DB06433
 Compound Name BBR-3438 Discontinued in Phase 2 [84]
Synonyms
Nortopixantrone; UNII-PH2639TAB4; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
    Click to Show/Hide
External Link
CID: 3038512
TTD: D01VPR
 Compound Name IPI-493 Discontinued in Phase 1 [85]
Synonyms
[(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
    Click to Show/Hide
External Link
CID: 9893658
TTD: D0BM6S
DrugBank: DB13023
 Compound Name Kanjinti Application submitted [30]
External Link
TTD: D0CW3U
 Compound Name Anti-CD9 mab Investigative [86]
Synonyms
ALB-6; Anti-CD9 mAb (gastric cancer); Anti-CD9 mAb (gastric cancer), Osaka University
    Click to Show/Hide
External Link
TTD: D09BPT
References
Ref 1 LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m(6) A-YTHDF2-dependent manner. Clin Transl Med. 2023 Mar;13(3):e1205. doi: 10.1002/ctm2.1205.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 3 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216873
Ref 4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. doi: 10.1038/nrd3657.
Ref 5 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 213871.
Ref 6 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12.
Ref 7 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
Ref 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
Ref 9 DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 Clinical pipeline report, company report or official report of EQRx
Ref 12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 13 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
Ref 14 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
Ref 15 Clinical pipeline report, company report or official report of Klus Pharma
Ref 16 Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
Ref 17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
Ref 18 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
Ref 19 Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917.
Ref 20 Clinical pipeline report, company report or official report of Kinaset Therapeutics
Ref 21 Clinical pipeline report, company report or official report of AstraZeneca
Ref 22 Clinical pipeline report, company report or official report of Pfzer
Ref 23 Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.
Ref 24 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. Expert Opin Ther Pat. 2017 Feb;27(2):127-143. doi: 10.1080/13543776.2017.1252753. Epub 2016 Nov 7.
Ref 25 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
Ref 26 Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. doi: 10.1016/s0960-894x(00)00051-2.
Ref 27 Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. doi: 10.1021/jm401546n. Epub 2013 Dec 20.
Ref 28 The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. doi: 10.1182/blood-2007-09-115030. Epub 2007 Dec 19.
Ref 29 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217759.
Ref 30 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 31 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228.
Ref 32 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
Ref 35 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
Ref 36 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 37 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
Ref 42 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 43 Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
Ref 44 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
Ref 45 ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
Ref 46 ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 47 Clinical pipeline report, company report or official report of Daiichi Sankyo.
Ref 48 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 49 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
Ref 51 ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
Ref 55 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
Ref 56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
Ref 57 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
Ref 59 Clinical pipeline report, company report or official report of plevitrexed.
Ref 60 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT04404595) Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers. U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 63 ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Ref 64 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 65 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 66 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 68 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
Ref 69 Clinical pipeline report, company report or official report of Sanofi
Ref 70 ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
Ref 73 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Ref 74 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 75 Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
Ref 76 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 77 ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
Ref 78 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 79 ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
Ref 80 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 81 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
Ref 84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
Ref 85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
Ref 86 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.